Lipoprotein (a) [Lp(a)]: Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Lipoprotein (a) – abbreviated Lp(a) – is a low‑density lipoprotein (LDL) particle to which a second protein, apolipoprotein(a), is covalently attached. This unique structure makes Lp(a) both pro‑atherogenic and pro‑thrombotic. Unlike LDL cholesterol, Lp(a) levels are 80–90% genetically determined and remain remarkably stable throughout life, influenced little by diet, exercise, or most standard lipid‑lowering therapies.

A raised Lp(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease (myocardial infarction, stroke, peripheral artery disease) and calcific aortic valve stenosis. Testing is recommended once in a lifetime to identify individuals with inherited high Lp(a) who may otherwise be missed by standard lipid panels. There is currently no widely approved drug specifically for lowering Lp(a), but emerging therapies offer future hope. The immediate value of knowing an elevated Lp(a) lies in intensifying the management of all other modifiable risk factors (LDL cholesterol, blood pressure, smoking, diabetes).

---

2. What does it measure

a. Units of measurement

Two different units are used globally; they are not interchangeable and conversion is unreliable due to isoform size heterogeneity.

· Nanomoles per litre (nmol/L) – the preferred, mass‑independent international unit.

· Milligrams per decilitre (mg/dL) – still widely reported; 1 nmol/L ≈ 0.416 mg/dL, but this varies by apolipoprotein(a) isoform size.

Always use the same laboratory and same method when comparing results.

b. Normal Range and Interpretation

There is no universal “normal” threshold; risk is continuous and graded. However, consensus statements define:

· Desirable / low risk: Lp(a) mass <30 mg/dL or particle <75 nmol/L.

· Intermediate / borderline: Lp(a) mass 30–50 mg/dL or particle 75–125 nmol/L.

· High risk: Lp(a) mass >50 mg/dL or particle >125 nmol/L.

· Very high risk: Lp(a) mass >100 mg/dL or particle >250 nmol/L.

Ethnic variation: Persons of African descent have naturally higher median Lp(a); the same absolute level confers similar relative risk. South Asians also tend to have higher levels than Caucasians.

---

3. Other factors connected to this

a. Direct correlation (factors that genuinely raise Lp(a))

· Genetics – LPA gene kringle‑IV type‑2 repeats; smaller isoform size → higher hepatic production → higher plasma Lp(a). This is the dominant determinant.

· Chronic kidney disease – particularly nephrotic syndrome; Lp(a) rises with proteinuria and falls after transplantation.

· Hypothyroidism – Lp(a) is often elevated and normalises with levothyroxine therapy.

· Uncontrolled diabetes – modest elevation; insulin may lower it.

· Oestrogen deficiency – menopause increases Lp(a); hormone replacement therapy (oral oestrogen) lowers it.

· Growth hormone – administration raises Lp(a).

· Pregnancy – Lp(a) rises physiologically in the third trimester.

b. Indirect correlation (factors that influence Lp(a) modestly or clinically insignificantly)

· Age – Lp(a) is stable in adulthood; no age‑related reference adjustment needed.

· Sex – no consistent independent effect after menopause adjustment.

· Lifestyle factors – Diet, physical activity, and body weight have negligible to no effect on Lp(a) concentration. This is a critical distinction from LDL cholesterol.

· Medications –

· Lower Lp(a):

· Niacin (nicotinic acid) – 20–30% reduction.

· PCSK9 inhibitors – 20–30% reduction.

· Oestrogen / HRT – 15–25% reduction.

· Aspirin – very modest reduction (≈5–10%) in some studies.

· Emerging RNA therapeutics (pelacarsen, olpasiran) – up to 80–90% reduction (investigational).

· Raise Lp(a):

· Statins – minimal, but some studies show a slight (5–10%) increase; clinical significance uncertain.

· Androgens / anabolic steroids.

· Nicotinic acid withdrawal – rebound.

· Inflammation – acute phase reaction may transiently lower Lp(a); do not measure during acute illness.

---

4. Disorders related to abnormal values

a. When elevated (the only clinically relevant abnormality)

· Premature atherosclerotic cardiovascular disease – particularly in those without traditional risk factors.

· Recurrent cardiovascular events despite well‑controlled LDL cholesterol.

· Familial hypercholesterolaemia – concomitant elevation of Lp(a) markedly amplifies risk.

· Calcific aortic valve stenosis – Lp(a) is a causal risk factor for both development and progression.

· Thrombotic events – Lp(a) inhibits fibrinolysis by competing with plasminogen; associated with venous thromboembolism in some but not all studies.

· Ischaemic stroke – especially in young adults and those of African descent.

Very high Lp(a) (>180 mg/dL or >430 nmol/L) may be seen in homozygous familial hypercholesterolaemia or severe Lp(a) hyperlipoproteinaemia; these individuals warrant specialist referral.

b. When low (no clinical concern)

· Extremely low or undetectable Lp(a) – no known adverse consequence. There is no “deficiency syndrome”.

---

5. Best way to address aberrant levels

Important principle: Lp(a) is stubbornly resistant to lifestyle modification. Do not advise a patient that diet, exercise, or over‑the‑counter supplements will meaningfully lower their Lp(a) – this is false and can create dangerous complacency. The appropriate response to elevated Lp(a) is:

1. Confirm – repeat once to verify (rarely necessary if first result clearly elevated).

2. Educate – explain the genetic nature and the importance of managing all other risk factors aggressively.

3. Treat the overall risk – not the isolated number.

---

a. Quick ways or using Medications

Lp(a)‑lowering pharmacotherapy (modest effect, available now):

· Niacin (nicotinic acid) –

· Active form: Only nicotinic acid (not niacinamide) lowers Lp(a).

· Dosing: Extended‑release formulations (e.g., 1–2 g daily) are preferred; immediate‑release causes more flushing.

· Effect: 20–30% reduction.

· Caution: Flushing (prostaglandin‑mediated; can be mitigated by taking aspirin 30 minutes before, starting low dose, titrating slowly), hepatotoxicity, hyperglycaemia, hyperuricaemia.

· Controversy: Despite Lp(a) reduction, large outcome trials (HPS2‑THRIVE) did not show cardiovascular benefit when added to statin, largely due to side effects. Niacin is now rarely used solely for Lp(a).

· PCSK9 inhibitors –

· Evolocumab, alirocumab – monoclonal antibodies; lower Lp(a) by 20–30% in addition to profound LDL reduction.

· Indication: Approved for secondary prevention and familial hypercholesterolaemia; the Lp(a) reduction is a welcome ancillary effect, not the primary indication.

· Route: Subcutaneous injection every 2–4 weeks.

· Lipoprotein apheresis –

· Weekly or biweekly extracorporeal removal of Lp(a) and LDL; acutely lowers Lp(a) by 60–70%.

· Indication: Very high Lp(a) (>60 mg/dL or >150 nmol/L) with progressive CVD despite maximal medical therapy. Only available in specialised centres; resource intensive.

Emerging therapies (investigational, not yet widely available):

· Pelacarsen – antisense oligonucleotide directed at hepatic apolipoprotein(a) mRNA; lowers Lp(a) by 70–90% in phase 2 trials; phase 3 cardiovascular outcome trial (Lp(a) HORIZON) is ongoing.

· Olpasiran – small interfering RNA (siRNA) similarly targeting apo(a); phase 2 showed >90% reduction.

· Muvalaplin – oral small molecule that inhibits Lp(a) assembly; early phase trials.

Do not self‑prescribe any of these agents; all require specialist oversight.

What does NOT work for lowering Lp(a):

· Statins – no meaningful reduction; may slightly raise it.

· Ezetimibe – neutral.

· Bile acid sequestrants – neutral.

· Fibrates – neutral or modest increase.

· Omega‑3 fatty acids – neutral.

---

b. Using Supplements or Holistic medicine

Honest appraisal: There are no dietary supplements proven to significantly lower Lp(a) in well‑controlled human trials. Claims to the contrary are based on weak, uncontrolled, or confounded studies.

The following have been investigated; none can be recommended specifically for Lp(a) reduction:

· Vitamin C – theoretical antioxidant benefit; does not lower Lp(a) concentration.

· L‑carnitine – conflicting data; likely ineffective.

· Coenzyme Q10 – no effect on Lp(a).

· Berberine – lowers LDL and triglycerides; no effect on Lp(a) in available studies.

· Red yeast rice – contains monacolin K (lovastatin); does not lower Lp(a).

· Garlic, guggul, artichoke leaf, plant sterols – no credible Lp(a) effect.

However, supplements can support overall cardiovascular health in individuals with high Lp(a). If used for this purpose, they must be chosen ecologically and in active forms:

· Omega‑3 fatty acids (EPA/DHA) – do not lower Lp(a), but reduce triglycerides and inflammation.

· Preferred source: Algae oil – plant‑based, sustainable, re‑esterified triglyceride form.

· Dose: ≥2 g combined EPA+DHA daily.

· Vitamin D3 (from lichen) – correct deficiency; deficiency is associated with adverse CVD outcomes.

· Coenzyme Q10 – may be useful if taking statins (to mitigate myalgia), but not for Lp(a).

· Magnesium (glycinate / citrate) – supports vascular health.

Ayurvedic / holistic approaches:

No traditional herb has demonstrated Lp(a) reduction. Ashwagandha, turmeric, guduchi, etc. may have anti‑inflammatory properties but do not lower Lp(a) specifically. They should not be promoted for this purpose. If used for general wellbeing, ensure extracts are standardised and free from synthetic folic acid / cyanocobalamin.

Critical caution: Avoid any proprietary “cholesterol formula” that claims to lower Lp(a) – most contain ineffective doses of plant sterols or red yeast rice and often include synthetic folic acid. Do not waste resources on these.

---

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

Diet has no meaningful effect on Lp(a) concentration. Promising a patient that a particular food or dietary pattern will lower their inherited Lp(a) is both inaccurate and unethical.

Nonetheless, diet is the cornerstone of global cardiovascular risk reduction. For a person with elevated Lp(a), meticulous control of LDL cholesterol, blood pressure, and glycaemia is imperative – and diet is central to achieving this.

Dietary strategy – hierarchy adhered:

1. Plant‑based (whole food, plant‑dominant):

· Emphasise legumes, intact whole grains, vegetables, fruits, nuts, seeds.

· Soluble fibre (oats, barley, psyllium, eggplant, okra, beans) lowers LDL cholesterol.

· Replace saturated fats (from coconut oil, palm oil, high‑fat dairy) with unsaturated fats (olive oil, avocado, nuts, seeds).

· Eliminate industrial trans fats and minimise ultra‑processed foods.

2. Fungi / algae:

· Mushrooms (shiitake, oyster, maitake) – contain beta‑glucans; modest LDL lowering.

· Spirulina, chlorella – may improve lipid profiles; no effect on Lp(a).

3. Biotechnology / lab‑grown:

· Mycoprotein (Quorn) – sustainable protein source; neutral or beneficial for LDL.

· Precision‑fermented dairy proteins – emerging; acceptable but not required.

4. Dairy / eggs:

· Permitted but not emphasised. Low‑fat yoghurt, kefir may be included.

· Eggs – limit if concomitant hypercholesterolaemia; yolk has no effect on Lp(a).

5. Meat / fish / poultry:

· Deliberately omitted. There is no nutritional necessity to consume animal products to manage high Lp(a) or global cardiovascular risk. Effective plant‑based and fermentation‑derived alternatives exist for every nutrient.

· Fish / fish oil – unnecessary when algae‑sourced omega‑3 is available.

Key dietary message:

The diet for high Lp(a) is identical to the optimal cardioprotective diet – one that is predominantly plant‑based, rich in fibre, low in saturated fat, and free from refined carbohydrates and added sugars. This approach will lower LDL cholesterol, improve insulin sensitivity, reduce blood pressure, and attenuate inflammation – all of which reduce the absolute risk imposed by high Lp(a).

---

6. How soon can one expect improvement and the ideal time frame to retest

· Lp(a) is inherently stable. In the absence of a specific intervention (niacin, PCSK9 inhibitor, oestrogen, apheresis, or investigational RNA therapy), levels do not change over months or years.

· If a therapeutic intervention is initiated:

· Niacin: Lp(a) reduction occurs within 4–8 weeks; retest at 3 months.

· PCSK9 inhibitors: Reduction evident at first measurement (usually 4–12 weeks); retest at 3–6 months.

· Oestrogen / HRT: Effect seen by 3 months.

· Apheresis: Immediate reduction pre‑ to post‑session; average pre‑apheresis level declines over weeks to months with regular treatment.

· RNA therapeutics: Rapid, deep reduction within 1–3 months.

· Retesting frequency:

· Baseline diagnosis: One confirmatory test is sufficient; if levels are borderline, repeat once after 2–3 months to establish stability.

· Monitoring without intervention: No need to repeat – Lp(a) will be essentially the same years later.

· Monitoring with intervention: Every 3–6 months until stable, then annually if continuing therapy.

---

Conclusion

Lipoprotein (a) is a largely immutable, genetically determined cardiovascular risk factor. An elevated level cannot be “fixed” by diet, exercise, or most supplements. The discovery of high Lp(a) is therefore not a therapeutic dead end, but a powerful call to action – it identifies an individual who will derive exceptional benefit from aggressive, evidence‑based management of all modifiable risk factors.

For the patient, this means:

· Achieving and maintaining an LDL cholesterol substantially lower than population targets (often <70 mg/dL or <1.8 mmol/L, sometimes <55 mg/dL).

· Optimal blood pressure control (<130/80 mmHg).

· Absolute avoidance of tobacco.

· A heart‑protective, ecologically sustainable plant‑forward diet.

· Regular physical activity.

· Consideration of aspirin in selected high‑risk individuals (prescriber decision).

For the clinician, it means:

· Not dismissing Lp(a) as “untreatable”.

· Not prescribing ineffective or ecologically harmful supplements.

· Recognising emerging RNA‑based therapies that may transform the management of this condition within the next few years.

Lipoprotein (a) teaches us an important lesson: not every risk factor is modifiable, but risk itself always is.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x